These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27881255)

  • 1. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
    Zhao YJ; Khoo AL; Lin L; Teng M; Wu TS; Chan MY; Lim BP
    Value Health Reg Issues; 2016 May; 9():22-27. PubMed ID: 27881255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
    Chin CT; Mellstrom C; Chua TS; Matchar DB
    Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
    Gasche D; Ulle T; Meier B; Greiner RA
    Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
    Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
    J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
    Theidel U; Asseburg C; Giannitsis E; Katus H
    Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
    Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
    J Manag Care Spec Pharm; 2018 Aug; 24(8):800-812. PubMed ID: 30058986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts.
    Wein B; Coslovsky M; Jabbari R; Galatius S; Pfisterer M; Kaiser C
    Int J Cardiol; 2017 Dec; 248():20-27. PubMed ID: 28823409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
    Nikolic E; Janzon M; Hauch O; Wallentin L; Henriksson M;
    Eur Heart J; 2013 Jan; 34(3):220-8. PubMed ID: 22719022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
    Coleman CI; Limone BL
    Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
    Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
    J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
    Okere AN; Ezendu K; Berthe A; Diaby V
    J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.